New Indicator for Response to Therapy in Pediatric Cancers Identified

Why It Matters

Identifying aneuploidy as a predictive biomarker offers a path to personalize treatment for relapsed pediatric cancers, potentially improving survival odds and guiding future drug development.

Key Takeaways

• High aneuploidy score predicts response to PARP inhibitor therapy
• Study enrolled 70 relapsed pediatric solid tumor patients across four countries
• Twelve patients achieved tumor shrinkage or stable disease over six months
• DNA‑repair gene alterations did not predict therapeutic benefit
• Aneuploidy biomarker could guide future adult and pediatric trials

Pulse Analysis

Pediatric oncology has long struggled with a paucity of actionable biomarkers, especially for relapsed solid tumors where cure rates dip below 30 %. The eSMART Phase I/II arm, conducted by the University of Birmingham and the Cancer Research UK Clinical Trials Unit, recruited 70 heavily pre‑treated children across four European nations. By pairing low‑dose irinotecan with the PARP inhibitor olaparib, investigators sought a tolerable regimen that could exploit DNA‑repair vulnerabilities common to both adult and pediatric malignancies.

The trial’s most striking insight emerged from a retrospective genomic analysis: patients whose tumors carried a high aneuploidy score were markedly more likely to experience tumor reduction or prolonged disease stability. This contrasts sharply with earlier expectations that mutations in DNA‑repair genes would drive sensitivity to PARP inhibition. In fact, the study found no correlation between those classic gene alterations and clinical benefit, positioning aneuploidy as a novel, tumor‑agnostic predictor for this therapeutic class.

If validated in larger cohorts, aneuploidy could become a cornerstone biomarker for selecting pediatric patients for DNA‑repair‑targeted trials, mirroring the precision‑medicine paradigm already established in adult oncology. Moreover, the universality of chromosomal instability suggests the metric might extend to adult cancers, streamlining cross‑age drug development. Ongoing research will need to clarify the biological mechanisms linking aneuploidy to PARP inhibitor efficacy and determine optimal cut‑off thresholds, but the current data already signal a shift toward more individualized, genomically informed care for children facing the toughest cancer diagnoses.